Stryker Corporation $SYK Shares Purchased by State Street Corp

State Street Corp boosted its position in Stryker Corporation (NYSE:SYK) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,254,407 shares of the medical technology company’s stock after purchasing an additional 311,507 shares during the quarter. State Street Corp’s holdings in Stryker were worth $5,374,731,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. VanderPol Investments L.L.C. increased its position in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC increased its position in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after purchasing an additional 28 shares during the last quarter. Stonebridge Capital Advisors LLC increased its position in shares of Stryker by 0.4% during the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after purchasing an additional 29 shares during the last quarter. Tcfg Wealth Management LLC increased its position in shares of Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares during the last quarter. Finally, Sompo Asset Management Co. Ltd. increased its position in shares of Stryker by 1.3% during the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 2,390 shares of the medical technology company’s stock worth $946,000 after purchasing an additional 30 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of Stryker stock opened at $312.14 on Friday. The business has a 50-day moving average of $316.40 and a 200 day moving average of $343.97. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The stock has a market capitalization of $119.66 billion, a price-to-earnings ratio of 36.13, a price-to-earnings-growth ratio of 1.93 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter last year, the business earned $2.84 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SYK. William Blair reissued an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Leerink Partners cut their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Jefferies Financial Group reissued a “buy” rating and set a $465.00 price objective on shares of Stryker in a research report on Wednesday, March 4th. Finally, Sanford C. Bernstein set a $410.00 price objective on Stryker in a research report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $395.33.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,264 shares of company stock worth $100,659,489 in the last three months. 4.60% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.